Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.11889/5245
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRabba, Abdullah K.
dc.contributor.authorSi, Luqin
dc.contributor.authorXue, Kewen
dc.contributor.authorLi, Ming
dc.contributor.authorLi, Gao
dc.date.accessioned2017-11-25T06:32:04Z
dc.date.available2017-11-25T06:32:04Z
dc.date.issued2011-04
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pubmed/21733405
dc.identifier.urihttp://hdl.handle.net/20.500.11889/5245
dc.description.abstractPURPOSE: To determine experimentally the intestinal permeability of the anticancer prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is intestinally excreted (exsorped) as a predictor of intestinal toxicity, and to assess the effect of p-glycoprotein (p-gp) inhibitors (verapamil as a model) on the permeability and toxicity of irinotecan. METHODS: Single pass intestinal perfusion of rat's whole length small intestines is applied to assess the permeability of the parent drug and quantify the intestinally excreted metabolite. The perfusion solution contained 30μg/ml of irinotecan (control group) without or with verapamil (verapamil group). A simple reversed phase HPLC method with UV detection is developed and validated for simultaneous determination of irinotecan and SN-38 using camptothecin as an internal standard. RESULTS: HPLC-UV method found to be simple, specific, accurate, and precise. Effective permeability coefficient of irinotecan found to be 4.9±1.7 10-3 mm/min and was doubled in verapamil group (P=0.007). Average cumulative amount of SN-38 exsorped found to be 29 ng/cm over 2 hours perfusion time which was decreased to 15 ng/cm in verapamil group (P=0.016). CONCLUSIONS: in situ intestinal perfusion method was successfully applied to quantify the permeability of irinotecan and the exsorption of SN-38 in the same experiment, in a manner that robustly reflects real in vivo situation. P-gp inhibition using verapamil found to significantly enhance the intestinal permeability of irinotecan and potentially decrease the intestinal toxicity due to SN-38 exposure.en_US
dc.language.isoen_USen_US
dc.subject.lcshIrinotecan - Permeability
dc.subject.lcshIntestinal absorption
dc.subject.lcshDrug interactions
dc.subject.lcshAntineoplastic agents
dc.subject.lcshPerfusion (Physiology)
dc.subject.lcshHigh performance liquid chromatography - Methodology
dc.titleIn situ intestinal perfusion of irinotecan : application to p-gp mediated drug interaction and introduction of an improved HPLC assayen_US
dc.typeArticleen_US
newfileds.departmentPharmacy - Nursing and Health Professionsen_US
newfileds.item-access-typeopen_accessen_US
newfileds.thesis-prognoneen_US
newfileds.general-subjectHuman Biology, Medicine and Health Sciences | الطب والعلوم الطبيةen_US
Appears in Collections:Fulltext Publications

Files in This Item:
File Description SizeFormat 
9718-26972-1-PB (1).pdf320.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.